Canadian Medical Association Journal, Vol 155, Issue 8 1053-1059, Copyright © 1996 by Canadian Medical Association

JOURNAL ARTICLE

Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials

S. C. Hood, D. Moher and G. G. Barber
Health Analysis and Modelling Group, Social and Economic Studies Division, Statistics Canada, Ottawa, Ont.

OBJECTIVE: To evaluate the efficacy of pentoxifylline therapy in improving the walking capacity of patients with moderate intermittent claudication. DATA SOURCES: A search of MEDLINE for trials published between 1976 and 1994 inclusive, and a bibliographic review of all articles retrieved. STUDY SELECTION: Randomized, placebo-controlled, double-blind clinical trials were selected that evaluated the pain-free walking distance (the distanced walked on a treadmill before the onset of calf pain) and the absolute claudication distance (the maximum distance walked on a treadmill) among patients with moderate intermittent claudication. Twelve study groups in 11 trials were included in the analysis. DATA EXTRACTION: In addition to information regarding the trial design, patient characteristics, dosages and treatment periods, the means and standard deviations were collected for both the pain-free walking and absolute claudication distances. Trial quality was also assessed. DATA SYNTHESIS: Overall, there was a statistically significant improvement in the pain-free walking distance after pentoxifylline therapy (weighted mean difference 29.4 m [95% confidence interval (CI) 13.0 to 45.9 m]); this finding was based on a total sample of 612 patients (308 in the treatment groups and 304 in the control groups). A significant improvement was also noted in the absolute claudication distance (weighted mean difference 48.4 m [95% CI 18.3 to 78.6 m]); this was based on a total sample of 511 patients (258 in the treatment group and 253 in the control group). In a sensitivity analysis of the pain-free walking distance, significant treatment effects and no statistically significant heterogeneity were found when only trials were included that were "medically eligible" (involved patients with stage II disease and a pain-free walking distance of 50 to 200 m). In a similar sensitivity analysis of the absolute claudication distance, the two conditions resulting in a significant treatment effect and no significant heterogeneity were the inclusion of "medically eligible" trials and those with a shorter treatment duration (13 weeks or less). CONCLUSION: Pentoxifylline therapy may be efficacious in improving the walking capacity of patients with moderate intermittent claudication. However, properly conducted clinical trials are required to provide a true estimate of the benefit.

This article has been cited by other articles:

				T De Backer, R Vander Stichele, P Lehert, and L Van Bortel Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data BMJ, March 10, 2009; 338(mar10_1): b603 - b603. [Abstract] [Full Text] [PDF]

				G. H. Guyatt, D. J. Cook, R. Jaeschke, S. G. Pauker, and H. J. Schunemann Grades of Recommendation for Antithrombotic Agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 123S - 131S. [Abstract] [Full Text] [PDF]

				M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]

				A. T. Hirsch, Z. J. Haskal, N. R. Hertzer, C. W. Bakal, M. A. Creager, J. L. Halperin, L. F. Hiratzka, W. R.C. Murphy, J. W. Olin, J. B. Puschett, et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1239 - 1312. [Full Text] [PDF]

				K. T. Delis The Case for Intermittent Pneumatic Compression of the Lower Extremity as a Novel Treatment in Arterial Claudication Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2005; 17(1): 29 - 42. [Abstract] [PDF]

				K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money Medical Management of Intermittent Claudication Vascular and Endovascular Surgery, September 1, 2004; 38(5): 391 - 399. [Abstract] [PDF]

				G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]

				M. A. Creager, D. W. Jones, J. D. Easton, J. L. Halperin, A. T. Hirsch, A. H. Matsumoto, P. T. O'Gara, R. D. Safian, G. L. Schwartz, and J. A. Spittell Atherosclerotic Vascular Disease Conference: Writing Group V: Medical Decision Making and Therapy Circulation, June 1, 2004; 109(21): 2634 - 2642. [Full Text] [PDF]

				K. J. Stewart, W. R. Hiatt, J. G. Regensteiner, and A. T. Hirsch Exercise Training for Claudication N. Engl. J. Med., December 12, 2002; 347(24): 1941 - 1951. [Full Text] [PDF]

				S. M Dean Pharmacologic treatment for intermittent claudication Vascular Medicine, November 1, 2002; 7(4): 301 - 309. [Abstract] [PDF]

				M. R. Jaff Pharmacotherapy for Peripheral Arterial Disease: Emerging Therapeutic Options Angiology, November 1, 2002; 53(6): 627 - 633. [Abstract] [PDF]

				L. Scanlon Review: pentoxifylline with standard compression treatment improves healing of venous leg ulcers Evid. Based Nurs., October 1, 2002; 5(4): 110 - 110. [Full Text] [PDF]

				S. Coccheri, G. Scondotto, G. Agnelli, E. Palazzini, and V. Zamboni Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study Eur. Heart J., July 1, 2002; 23(13): 1057 - 1065. [Abstract] [Full Text] [PDF]

				Managing peripheral arterial disease in primary care DTB, January 1, 2002; 40(1): 5 - 8. [Abstract] [Full Text] [PDF]

				L. T Cooper Jr, W. R Hiatt, M. A Creager, J. G Regensteiner, W. Casscells, J. M Isner, J. P Cooke, and A. T Hirsch Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication Vascular Medicine, November 1, 2001; 6(4): 235 - 239. [Abstract] [PDF]

				W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]

				M. Lievre, S. Morand, B. Besse, J.-N. Fiessinger, and J.-P. Boissel Oral Beraprost Sodium, a Prostaglandin I2 Analogue, for Intermittent Claudication : A Double-Blind, Randomized, Multicenter Controlled Trial Circulation, July 25, 2000; 102(4): 426 - 431. [Abstract] [Full Text] [PDF]

				P Gresele, R Migliacci, G D. Sante, G. Nenci, and CRAMPS Investigator Group Effect of cloricromene on intermittent claudication. A randomized, double-blind, placebo-controlled trial in patients treated with aspirin: effect on claudication distance and quality of life Vascular Medicine, May 1, 2000; 5(2): 83 - 89. [Abstract] [PDF]

				B. Girolami, E. Bernardi, M. H. Prins, J. W. ten Cate, R. Hettiarachchi, P. Prandoni, A. Girolami, and H. R. Buller Treatment of Intermittent Claudication With Physical Training, Smoking Cessation, Pentoxifylline, or Nafronyl: A Meta-analysis Arch Intern Med, February 22, 1999; 159(4): 337 - 345. [Abstract] [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-1996, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.